Bazedoxifene

Excerpt

Bazedoxifene is a selective estrogen receptor modulator used to manage osteoporosis in postmenopausal women. Osteoporosis is characterized by the gradual decline in overall bone density that exposes patients to an increased risk of proximal fractures. Approved by the U.S. Food and Drug Administration (FDA) as a combination drug alongside conjugated estrogens, bazedoxifene is crucial in addressing vasomotor symptoms associated with menopause and preventing postmenopausal osteoporosis. This activity explores the approved indications, mechanisms of action, proper administration, potential adverse events, and contraindications of bazedoxifene. Participants gain insights to deliver optimal care to high-risk women with osteoporosis and associated menopausal symptoms, especially in cases where conventional therapies are contraindicated.